Albireo Pharma/ US01345P1066 /
3/2/2023 10:00:00 PM | Chg. - | Volume | Bid1:36:55 AM | Ask1:56:51 AM | High | Low |
---|---|---|---|---|---|---|
44.1500USD | - | 1.24 mill. Turnover: 52.59 mill. |
44.1000Bid Size: 1,000 | 44.3000Ask Size: 300 | 44.9000 | 43.9900 |
GlobeNewswire
11/1/2023
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
GlobeNewswire
10/23/2023
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire
3/29/2022
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Sy...
GlobeNewswire
2/14/2022
Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare...
GlobeNewswire
12/2/2021
Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
GlobeNewswire
11/12/2021
Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Gen...